Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Physiol Biochem ; 70(3): 791-800, 2014 Sep.
Article de Anglais | MEDLINE | ID: mdl-25034332

RÉSUMÉ

The aim of the present study was to assess whether the protective effects of ischemic preconditioning (PC) are associated with activation of the mitochondrial ATP-sensitive potassium channels (mitoKATP) and if there is any relationship between the activity of these channels and the mitochondrial permeability transition pore (MPTP) opening in ischemic-reperfused rat hearts under different nutritional conditions. Langendorff-perfused hearts of fed and 24-h fasted rats were exposed to 25 min of no-flow global ischemia plus 30 min of reperfusion. Fasting accelerated functional recovery and attenuated MPTP opening. The mitoKATP blocker, 5-hydroxydecanoic (HD), did not influence functional recovery and MPTP opening induced by ischemia-reperfusion in the fed hearts but partially reversed the beneficial effects of fasting. PC and the mitoKATP opener, diazoxide (DZ), improved functional recovery, preserved cell viability, and inhibited MPTP opening in both fed and fasted hearts. The protection elicited by PC and DZ on contractile recovery and MPTP opening was reversed by HD, which did not affect cell viability. Altogether, these results argue for a role of mitoKATP and its impact on preservation mitochondrial inner membrane permeability as a relevant factor in the improvement of contractile function in the ischemic-reperfused rat heart. They also suggest that the functional protection elicited by PC may be related to this mechanism.


Sujet(s)
Préconditionnement ischémique myocardique/méthodes , Protéines de transport de la membrane mitochondriale/métabolisme , Lésion de reperfusion myocardique/métabolisme , Lésion de reperfusion myocardique/prévention et contrôle , Canaux potassiques/métabolisme , Animaux , Cardiotoniques/pharmacologie , Acides capriques/pharmacologie , Désoxyglucose/métabolisme , Diazoxide/pharmacologie , Jeûne/métabolisme , Femelle , Hydroxyacides/pharmacologie , Techniques in vitro , Mitochondries du myocarde/effets des médicaments et des substances chimiques , Mitochondries du myocarde/métabolisme , Protéines de transport de la membrane mitochondriale/effets des médicaments et des substances chimiques , Pore de transition de perméabilité mitochondriale , Lésion de reperfusion myocardique/physiopathologie , Inhibiteurs des canaux potassiques/pharmacologie , Canaux potassiques/agonistes , Rats , Rat Wistar
2.
J Physiol Sci ; 62(4): 333-41, 2012 Jul.
Article de Anglais | MEDLINE | ID: mdl-22614393

RÉSUMÉ

Ischemic postconditioning (IPOC) protects the myocardium from ischemic-reperfusion injury, improving functional recovery and cell viability. This protection is concurrent with stimulation of glycogen breakdown, increased mitochondrial ATP synthesis and content, maintenance of reduced-to-oxidized glutathione ratio (GSH/GSSG), and decreased oxidative damage. The present study's objective was to assess whether these effects are associated with increased resistance to mitochondrial permeability transition pore (MPTP) opening. The effects of the AMP-activated protein kinase (AMPK) inhibitor, compound C (CC), were measured to investigate association with AMPK. Mitochondria removed from postconditioned hearts required higher calcium levels to induce MPTP opening. Improved functional recovery, increased glycogen mobilization, maintenance of the GSH/GSSG ratio, decreased oxidative damage, and increased resistance to MPTP opening were abrogated when the hearts were postconditioned in the presence of CC, without affecting preservation of cell viability. Although AMPK appears to play a role in IPOC, it would not be the major cellular mediator.


Sujet(s)
AMP-Activated Protein Kinases/antagonistes et inhibiteurs , Postconditionnement ischémique , Mitochondries du myocarde/effets des médicaments et des substances chimiques , Protéines de transport de la membrane mitochondriale/physiologie , Pyrazoles/pharmacologie , Pyrimidines/pharmacologie , Animaux , Survie cellulaire/effets des médicaments et des substances chimiques , Femelle , Glutathion/métabolisme , Disulfure de glutathion/métabolisme , Pore de transition de perméabilité mitochondriale , Lésion de reperfusion myocardique/prévention et contrôle , Stress oxydatif , Rats , Rat Wistar
3.
J Physiol Sci ; 61(4): 303-12, 2011 Jul.
Article de Anglais | MEDLINE | ID: mdl-21547611

RÉSUMÉ

The effects of ischemic-postconditioning (IPOC) on functional recovery and cell viability of ischemic-reperfused hearts from fed and fasted rats were studied in relation to triacylglycerol and glycogen mobilization, ATP content, glucose-6-phosphate dehydrogenase activity and reduced/oxidized glutathione (GSH/GSSG). Oxidative damage was estimated by measuring thiobarbituric acid reactive substances (TBARS). IPOC improved contractile recovery and cell viability in the fed but attenuated them in the fasted hearts. In both groups ischemia lowered glycogen. IPOC further reduced it. Triacylglycerol remained unchanged during ischemia-reperfusion in both groups, but triacylglycerol mobilization was activated by IPOC in the fasted group. ATP was increased by IPOC in the fed hearts, but lowered in the fasted ones, which appeared to be associated with the rates of ATP synthesis in isolated mitochondria. In the fed hearts IPOC raised glucose-6-phosphate dehydrogenase activity and GSH/GSSG, and lowered TBARS. These results suggest that IPOC effects are associated with changes in the ATP supply, mobilization of energy sources and glutathione antioxidant ratio.


Sujet(s)
Métabolisme énergétique/physiologie , Jeûne/physiologie , Coeur/physiopathologie , Postconditionnement ischémique , Ischémie myocardique/physiopathologie , Reperfusion myocardique , Adénosine triphosphate/métabolisme , Animaux , Pression sanguine/physiologie , Survie cellulaire/physiologie , Femelle , Glucose 6-phosphate dehydrogenase/métabolisme , Glutathion/métabolisme , Disulfure de glutathion/métabolisme , Glycine/analogues et dérivés , Glycine/pharmacologie , Glycogène/métabolisme , Coeur/effets des médicaments et des substances chimiques , Rythme cardiaque/physiologie , Mitochondries du myocarde/métabolisme , Contraction myocardique/physiologie , Ischémie myocardique/métabolisme , Lésion de reperfusion myocardique/prévention et contrôle , Myocarde/enzymologie , Myocarde/métabolisme , Myocarde/anatomopathologie , Myocytes cardiaques/anatomopathologie , Rats , Rat Wistar , Substances réactives à l'acide thiobarbiturique/métabolisme , Triglycéride/métabolisme , Dysfonction ventriculaire gauche/physiopathologie
4.
Am J Respir Crit Care Med ; 163(1): 55-60, 2001 Jan.
Article de Anglais | MEDLINE | ID: mdl-11208626

RÉSUMÉ

We studied surfactant kinetics on Day 1 of life in 11 preterm infants on mechanical ventilation by infusing stable isotope labeled palmitic (PA) and linoleic acid (LLA). Six infants received exogenous surfactant for the treatment of respiratory distress syndrome (RDS) and five did not meet treatment criteria because of minimal or no disease. The isotopic enrichment of plasma free PA and LLA and of surfactant phosphatidylcholine PA (PC-PA) and LLA (PC-LLA) from tracheal aspirates was measured by mass spectrometry. Significant isotopic enrichment could be measured in PC-PA and PC-LLA from all patients. The fractional synthesis rate (FSR) of PC-LLA was higher than that of PC-PA (22.7 +/- 15.9 versus 12.1 +/- 7.7% per day, p = 0.018). Half-life (HL) of PC-PA was longer than that of PC-LLA (94.7 +/- 18.8 versus 46.6 +/- 32.6 h, p = 0.028). Patients who received exogenous surfactant had longer secretion times (ST) and delayed peak times (PK) but FSR and HL were unaffected. We concluded that: (1) surfactant kinetics can be measured in preterm infants with stable isotope labeled lipids; (2) surfactant FSR and HL calculated with PA and LLA gave different results; (3) patients treated with exogenous surfactant had similar FSRs compared with the nontreated subjects but had longer ST and delayed PK; (4) FSR from plasma free fatty acids (present study) was higher than that from plasma glucose in our previous work (Bunt JEH, Zimmermann LJI, Wattimena D, van Beek R, Sauer PJJ, Carnielli VP. Am J Respir Crit Care Med 1998;157:810-814) in a comparable population of preterm infants with RDS.


Sujet(s)
Maladies du prématuré/imagerie diagnostique , Maladies du prématuré/métabolisme , Surfactants pulmonaires/métabolisme , Syndrome de détresse respiratoire du nouveau-né/imagerie diagnostique , Syndrome de détresse respiratoire du nouveau-né/métabolisme , Humains , Nouveau-né , Prématuré , Isotopes , Acide linoléique , Acide palmitique , Scintigraphie
5.
Am J Respir Crit Care Med ; 161(5): 1584-9, 2000 May.
Article de Anglais | MEDLINE | ID: mdl-10806159

RÉSUMÉ

Little is known about surfactant metabolism in newborn infants, since radioactive isotopes cannot be used in humans. We describe here a new method for studying exogenous surfactant pharmacokinetics in vivo. We measured surfactant half-life, pool size, and turnover time in eight preterm infants (gestational age: 30 +/- 2 wk; birth weight: 1,416 +/- 202 g) who were mechanically ventilated because of infant respiratory distress syndrome. We administered two doses of 100 mg/kg each of a natural porcine surfactant with (13)C-labeled dipalmitoylphosphatidylcholine as a tracer. The (13)C enrichment of surfactant disaturated phosphatidylcholine (DSPC) was measured in serial tracheal aspirates by gas chromatography-mass spectrometry. The DSPC half-life was 34.2 +/- 9.4 h (mean +/- SD; range: 21.8 to 45.9 h). The apparent DSPC pool sizes were 5.8 +/- 6.1 mg/kg (range: 0.1 to 17.0 mg/kg) and 17.3 +/- 13.6 mg/kg (range: 3.3 to 41.0 mg/kg) at the time of the first and second surfactant doses, respectively. We present a novel and safe method that allows the tracing of exogenous surfactant phosphatidylcholine, the major lipid component of pulmonary surfactant, in infants who receive exogenous surfactant. This method could be a valuable tool for studying: (1) therapies that enhance lung/surfactant maturation; (2) the dosing and timing of surfactant therapy in different lung diseases; and (3) the comparison of different surfactant preparations.


Sujet(s)
Produits biologiques , Maladies du prématuré/métabolisme , Phospholipides , Surfactants pulmonaires/pharmacocinétique , Syndrome de détresse respiratoire du nouveau-né/métabolisme , 1,2-Dipalmitoylphosphatidylcholine/pharmacocinétique , Isotopes du carbone , Chromatographie gazeuse-spectrométrie de masse , Période , Humains , Nouveau-né , Maladies du prématuré/thérapie , Surfactants pulmonaires/usage thérapeutique , Ventilation artificielle , Syndrome de détresse respiratoire du nouveau-né/thérapie , Trachée/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...